Meeting
2023 ASCO Annual Meeting
Overall survival of patients with BRAF-mutant metastatic colorectal cancer treated with encorafenib-cetuximab in a real-world nationwide study in the Netherlands.
Authors
Sietske C.M.W. van Nassau
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
Sietske C.M.W. van Nassau , Koen Zwart , Frederieke van der Baan , Miriam Koopman , Anna J. van Gestel , Petur Snaebjornsson , Geraldine R. Vink , Jeanine Roodhart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3589)
DOI
10.1200/JCO.2023.41.16_suppl.3589
Abstract #
3589
Poster Bd #
289
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Retrospective analysis of adherence and persistence of encorafenib in combination with cetuximab among patients with BRAF metastatic CRC in the United States (US).
First Author: Aparna Raj Parikh
Poster
2023 ASCO Annual Meeting
Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAF V600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment.
First Author: Guglielmo Vetere
Poster
2023 ASCO Gastrointestinal Cancers Symposium
SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600E–mutant microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC).
First Author: Scott Kopetz
Poster
2023 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz